|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:advocates_for
|
obtained from participants
|
|
gptkbp:analysis
|
conducted
statistical methods used
|
|
gptkbp:analyzes
|
multiple locations
|
|
gptkbp:business_model
|
received
|
|
gptkbp:clinical_trial
|
gptkb:Clinical_Trials.gov
Phase 3
published
adaptive design
regulated by authorities
expected in 2021
|
|
gptkbp:collaborations
|
gptkb:international_partners
gptkb:Biontech
|
|
gptkbp:collection
|
ongoing
|
|
gptkbp:criteria
|
under investigation
|
|
gptkbp:developer
|
gptkb:Cure_Vac
|
|
gptkbp:dosage_form
|
two doses
|
|
gptkbp:end_date
|
gptkb:2021
|
|
gptkbp:finale_date
|
prevention of severe COVID-19
prevention of symptomatic COVID-19
|
|
gptkbp:healthcare
|
assessed
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cure Vac's COVID-19 vaccine trial
|
|
gptkbp:is_monitored_by
|
adverse events
independent data monitoring committee
|
|
gptkbp:is_studied_in
|
randomized controlled trial
|
|
gptkbp:is_tested_for
|
Phase 2b/3
|
|
gptkbp:is_vulnerable_to
|
gptkb:vaccine
ongoing
pending
planned
secured
reported
lipid nanoparticles
under evaluation
cold chain required
C Vn Co V
messenger RNA technology
|
|
gptkbp:launch_date
|
December 2020
|
|
gptkbp:location
|
gptkb:Europe
|
|
gptkbp:manager
|
intramuscular injection
|
|
gptkbp:participants
|
over 40,000
immunogenicity
|
|
gptkbp:partnerships
|
various institutions
|
|
gptkbp:population
|
adults and elderly
|
|
gptkbp:provides_information_on
|
encouraged
|
|
gptkbp:publishes
|
peer-reviewed journals
|
|
gptkbp:receives_funding_from
|
public and private investment
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
submitted to EMA
|
|
gptkbp:research_focus
|
COVID-19 prevention
|
|
gptkbp:result
|
efficacy data
|
|
gptkbp:safety_features
|
continuous
conducted regularly
assessed
|
|
gptkbp:side_effect
|
mild to moderate
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:technology
|
innovative
|
|
gptkbp:treatment
|
monitored
|
|
gptkbp:bfsParent
|
gptkb:Cure_Vac_AG
|
|
gptkbp:bfsLayer
|
4
|